Brittanni Elliott
Psychiatric/Mental Health · Richmond, INNPI 1326821984
Payments from drug & device makers
Across 142 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$683
- Vanda Pharmaceuticals Inc.$169
- Otsuka America Pharmaceutical, Inc.$152
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Takeda Pharmaceuticals U.S.A., Inc.$121
- Neurocrine Biosciences, Inc.$118
- plus $690 from 13 others
What the payments were for
- Food & beverage$2,067100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $683 |
| Vanda Pharmaceuticals Inc. | 7 | $169 |
| Otsuka America Pharmaceutical, Inc. | 8 | $152 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $121 |
| Neurocrine Biosciences, Inc. | 6 | $118 |
| Teva Pharmaceuticals USA, Inc. | 5 | $104 |
| Lundbeck LLC | 6 | $103 |
| Alkermes, Inc. | 4 | $81 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Corium, LLC | 4 | $63 |
| Johnson & Johnson | 3 | $59 |
| Indivior Inc. | 2 | $49 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Tris Pharma Inc | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
How this compares
$2,067 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 12 | $920 |
| Alprazolam | 33 | $128 |
| Lamotrigine | 11 | $45 |
| Fluoxetine Hcl | 18 | $41 |
| Clonazepam | 14 | $38 |
| Quetiapine Fumarate | 18 | $37 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Richmond
- Courtney FullmerRichmond$6K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.